FDA approves Vaxelis 6-in-1 pediatric vaccine

  • FDA

  • curated by Yael Waknine
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The FDA has approved a 6-in-1 intramuscular vaccine (Vaxelis) for use in children aged 6 weeks through
  • The 3-dose series protects against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type B.
  • The series should be followed by 1 additional dose of pertussis vaccine.

Why this matters

  • Combination vaccines reduce the number of injections necessary.

Clinical studies

  • Approval was based on noninferiority demonstrated in 2 US clinical studies of children randomly assigned to standard vaccination or Vaxelis at age 2, 4, and 6 months; all received rotavirus and pneumococcal vaccinations.
  • Funding: Joint partnership between Merck & Co., Inc., Kenilworth, NJ, USA and Sanofi.

Key points

  • Use with caution in children with:
    • A history of fever ≥40.5°C (≥105°F), hypotonic-hyporesponsive episode or persistent, inconsolable crying for ≥3 hours within 48 hours after pertussis-containing vaccination.
    • Seizures within 3 days after pertussis-containing vaccination.
  • Guillain-Barré syndrome risk may be increased if prior case was diagnosed within 6 weeks of tetanus toxoid-containing vaccination.
  • Some premature infants have experienced postvaccination apnea.
  • Vaccination may interfere with urine antigen tests for H influenzae type B.
  • Adverse events may include irritability, crying, injection site pain, somnolence, injection site erythema, decreased appetite, fever, injection site swelling, and vomiting.

Prescribing information